Markus J. Seibel MD, PhD, FRCAP

Bone Research Program
ANZAC Research Institute
Gate 3, Hospital Road
Concord, NSW 2139
e-mail: Opens window for sending emailMarkus.Seibel(at)

Academic appointments

Professor and Chair of Endocrinology, The University of Sydney Director, Bone Res. Program, ANZAC Res. Institute, Sydney Director, Department of Endocrinology & Metabolism, CRGH, Sydney LHD

Other Professional Activities


Chairman, ASBMR working group on biochemical markers of bone turnover (elected)

2004– Board Member, ASBMR working group on biochemical markers of bone turnover

Board of Directors, German Academy of Bone and Joint Sciences (invited)


President, German Academy of Bone and Joint Sciences (elected)


Scientific Advisory Board, International Osteoporosis Foundation, re-elected 2003

2000–2003 Member, Professional Practice Committee, ASBMR (elected)

Fellow, Royal Australasian College of Physicians


Member, Medical & Scientific Committee, Osteoporosis Australia (invited)


Member of Board of Directors, Inst of Joint and Bone Disease, Sydney (invited)

2006– Member and co-chair, RACGP guidelines writing group on osteoporosis (invited)

Member, Council, Australian and New Zealand Bone & Mineral Society.(elected)


President Elect, Australian and New Zealand Bone & Mineral Society


President, Australian and New Zealand Bone & Mineral Society


Immediate Past-President, Australian and New Zealand Bone & Mineral Society


Chair, SOS National Fracture Alliance, Australia


Board of Directors and Treasurer, International Federation of Musculoskeletal Research Societies

Major research achievements

Markus has an extensive track record in basic and clinical research into musculoskeletal health and biology. Since 1986, his research has been continuously funded through competitive grants from the NHMRC, ARC, PCFA, DVA, NSW government, the Commonwealth Institute, German Research Council, the German Cancer Foundation, the International Osteoporosis Foundation and other agencies. He has published over 400 scientific papers, including reports in JCI, PNAS, NEJM, BMJ, JBMR, Cancer Res, Development, JBC, Ann Int Med, Arthr & Rheum and The Lancet Diabetes & Endocrinology. He is the editor of 6 books, some of which have appeared in several editions.

Over the past 12 years, his research into the role of the bone microenvironment in skeletal cancer metastases gained international scientific and media attention (Cancer Res. 2007, 2010, JBMR 2014 etc.). In addition, he and his team contributed to our understanding of glucocorticoid action in and on bone and systemic energy metabolism. This includes the discovery of new mechanisms in the regulation of mesenchymal cell differentiation and osteoblast signalling (JBC 2008, Development 2009, Steroids 2010, Bone 2011) and the osteoblast-mediated actions of glucocorticoids on systemic fuel metabolism (J Clin Invest 2012, Lancet Diab Endocrinol 2014, TEM 2014). Similarly, the team's contributions to the controversial area of FSH effects on bone gained international recognition (Cell 2006, PNAS 2010). Collaborative research into the role of androgens on bone density and fracture risk in men has influenced current thinking in the area of male bone health (Arch Int Med 2008, Ann Int Med 2010). Further clinical work includes atypical femur fractures (NEJM 2010, MJA 2010, Bone 2011, JAMA 2011) and models of care for secondary fracture prevention (Osteoporosis Intl 2010, 2011, 2012, 2014, MJA 2011). He is a CI of the successful CHAMP study into male health which has gained an international reputation for high quality output (e.g. BMJ 2011, 2014, JCE&M 2014a, 2014b, 2015, JBMR 2010, 2014, Bone 2011).